Suven Life Sciences has secured four product patents for new chemical entities that are targeted at potential treatment of disorders associated with the brain.
These patents are from Australia, Canada, Korea and New Zealand. Their validity will be through 2026 to 2028, according to a company release.
The granted claims of the patents include the class of selective compounds discovered by Suven.
These compounds are being developed as therapeutic agents in the treatment of disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these patents, Suven has a total of 45 patents — Australia (15), Canada (9), Korea (8) and New Zealand (13). The company plans to out-license them at various phases of clinical development, said Venkat Jasti, Chief Executive Officer.
Suven Life Science, a biopharmaceutical company has 12 therapeutic drug candidates at pre-clinical stage of development targeting the rare disorders, he said.